Y-mAbs Therapeutics, Inc.

NASDAQ:YMAB

13.74 (USD) • At close September 13, 2024
Bedrijfsnaam Y-mAbs Therapeutics, Inc.
Symbool YMAB
Munteenheid USD
Prijs 13.74
Beurswaarde 612,389,052
Dividendpercentage 0%
52-weken bereik 4.69 - 20.9
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thomas Gad
Website https://www.ymabs.com

An error occurred while fetching data.

Over Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory

Vergelijkbare Aandelen

Affimed N.V. logo

Affimed N.V.

AFMD

4 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

15.73 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

GH Research PLC logo

GH Research PLC

GHRS

8.3 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

3.59 USD

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

4.03 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.68 USD

Ocugen, Inc. logo

Ocugen, Inc.

OCGN

1.21 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)